NASDAQ:BIAF
Bioaffinity Technologies, Inc. Stock News
$2.37
+0.150 (+6.76%)
At Close: May 21, 2024
bioAffinity Technologies Reports Record Q1 Revenue Driven by Accelerating Growth of CyPath® Lung Sales and Increased Laboratory Volumes
09:15am, Wednesday, 15'th May 2024
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technology reports record Q1 2024 revenue driven by accelerating sales of lung cancer diagnostic CyPath Lung.
bioAffinity Technologies News Update
08:00am, Thursday, 02'nd May 2024
SAN ANTONIO--(BUSINESS WIRE)-- #ATS--bioAffinity reports ramp in sales of CyPath® Lung, expanded sales team, new Patient Coach and upcoming presentation at American Thoracic Society.
bioAffinity Technologies Advances New Product Development Initiatives to Accelerate Next Phase of Growth
08:00am, Wednesday, 24'th Apr 2024
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies is developing diagnostics based on its proprietary platform for use with BAL fluid to detect lung cancer and to detect COPD.
bioAffinity Technologies Expands Campaign to Support American Cancer Society Initiative for Lung Cancer Screening
08:00am, Tuesday, 09'th Apr 2024
SAN ANTONIO--(BUSINESS WIRE)-- #ACS--bioAffinity Technologies and the American Cancer Society are expanding their campaign to raise funds for lung cancer screening.
JERSEY CITY, N.J. , March 8, 2024 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that bioAffinity Technologies, In
bioAffinity Technologies Announces Closing of $2.5 Million Registered Direct Offering and Concurrent Private Placement
12:45pm, Friday, 08'th Mar 2024
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies closed a securities purchase agreement with institutional investors for gross proceeds of approximately $2.5 million.
WallachBeth Capital Announces Pricing of BioAffinity Technologies $2.5 Million Registered Direct Offering and Concurrent Private Placement
10:45am, Wednesday, 06'th Mar 2024
JERSEY CITY, N.J. , March 6, 2024 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that BioAffinity Technologies (NA
bioAffinity Technologies Announces Pricing of $2.5 Million Registered Direct Offering and Concurrent Private Placement
09:46am, Wednesday, 06'th Mar 2024
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies announces it has entered into a securities purchase agreement with institutional investors.
bioAffinity Technologies Reports Accelerating Sales Growth of CyPath® Lung
08:00am, Tuesday, 05'th Mar 2024
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies reports 375% growth in sales of CyPath Lung tests in recent months.
bioAffinity Technologies In The News
08:00am, Tuesday, 30'th Jan 2024
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--Summary of the latest news about bioAffinity Technologies.
bioAffinity Technologies Announces Award of Therapeutic Patent for Treatment of Cancer
08:00am, Tuesday, 23'rd Jan 2024
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--Indian Patent Office issues patent to bioAffinity Technologies for porphyrin compounds related to targeted cancer treatment.
bioAffinity Technologies In the News
08:00am, Monday, 08'th Jan 2024
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--A summary of latest news about bioAffinity Technologies and CyPath® Lung, its noninvasive test for the detection of early-stage lung cancer.
bioAffinity Technologies and BioVie Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV
09:00am, Friday, 05'th Jan 2024
ORLANDO, FL / ACCESSWIRE / January 5, 2024 / RedChip Companies will air interviews with bioAffinity Technologies, Inc. (NASDAQ:BIAF) and BioVie, Inc. (NASDAQ:BIVI) on The RedChip Small Stocks Big Mone
bioAffinity Technologies Appoints Jamie Platt, Ph.D., to its Board of Directors
08:00am, Tuesday, 05'th Dec 2023
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--Jamie Platt, Ph.D., joins the bioAffinity Technologies Board of Directors.
CMS Posts Final Payment Determination for bioAffinity Technologies' CyPath® Lung Effective January 2024
08:00am, Thursday, 30'th Nov 2023
SAN ANTONIO,--(BUSINESS WIRE)-- #BIAF--CMS has made a final determination for payment for CyPath® Lung, a noninvasive test for early-stage lung cancer, for the 2024 calendar year.
